This clinical trial is for men and women who have Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia.
 
The purpose of this research is to gather information on the safety and effectiveness of PBCAR0191. PBCAR0191 is a new investigational treatment for certain types of blood cancers, such as leukemia and lymphoma, and is made from a type of blood cells known as T cells. 

Investigational means that PBCAR0191 has not yet been approved by the United States Food and Drug Administration (FDA).

The T cells in PBCAR0191 come from people who have donated their blood. The donated T cells have been genetically changed so that they may be able to kill some types of cancer cells. 
     
All participants will receive PBCAR0191 through an IV infusion at a dose determined by the study team. Participation in this research will last about 24 months.